Document Detail

The Role of Bioactive Lipids in Stem Cell Mobilization and Homing: Novel Therapeutics for Myocardial Ischemia.
Jump to Full Text
MedLine Citation:
PMID:  24672794     Owner:  NLM     Status:  Publisher    
Despite significant advances in medical therapy and interventional strategies, the prognosis of millions of patients with acute myocardial infarction (AMI) and ischemic heart disease (IHD) remains poor. Currently, short of heart transplantation with all of its inherit limitations, there are no available treatment strategies that replace the infarcted myocardium. It is now well established that cardiomyocytes undergo continuous renewal, with contribution from bone marrow (BM)-derived stem/progenitor cells (SPCs). This phenomenon is upregulated during AMI by initiating multiple innate reparatory mechanisms through which BMSPCs are mobilized towards the ischemic myocardium and contribute to myocardial regeneration. While a role for the SDF-1/CXCR4 axis in retention of BMSPCs in bone marrow is undisputed, its exclusive role in their mobilization and homing to a highly proteolytic microenvironment, such as the ischemic/infarcted myocardium, is currently being challenged. Recent evidence suggests a pivotal role for bioactive lipids in the mobilization of BMSPCs at the early stages following AMI and their homing towards ischemic myocardium. This review highlights the recent advances in our understanding of the mechanisms of stem cell mobilization, provides newer evidence implicating bioactive lipids in BMSPC mobilization and differentiation, and discusses their potential as therapeutic agents in the treatment of IHD.
Yuri M Klyachkin; Anush V Karapetyan; Mariusz Z Ratajczak; Ahmed Abdel-Latif
Related Documents :
12153664 - Two-dimensional and m-mode echocardiography of the fetal coronary sinus.
16970714 - The impact of marathon running upon ventricular function as assessed by 2d, doppler, an...
10832624 - Reduced early diastolic inflow velocities in the antero-posterior transverse direction ...
23074634 - Surgical repair of post-infarct true posterobasal ventricular aneurysm with mitral valv...
15972934 - Low toenail chromium concentration and increased risk of nonfatal myocardial infarction.
22828754 - Preprocedural imaging for patients with atrial fibrillation and heart failure.
Publication Detail:
Type:  REVIEW     Date:  2014-1-6
Journal Detail:
Title:  BioMed research international     Volume:  2014     ISSN:  2314-6141     ISO Abbreviation:  Biomed Res Int     Publication Date:  2014  
Date Detail:
Created Date:  2014-3-27     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101600173     Medline TA:  Biomed Res Int     Country:  -    
Other Details:
Languages:  ENG     Pagination:  653543     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): Biomed Res Int
Journal ID (iso-abbrev): Biomed Res Int
Journal ID (publisher-id): BMRI
ISSN: 2314-6133
ISSN: 2314-6141
Publisher: Hindawi Publishing Corporation
Article Information
Download PDF
Copyright © 2014 Yuri M. Klyachkin et al.
Received Day: 30 Month: 4 Year: 2013
Revision Received Day: 13 Month: 8 Year: 2013
Accepted Day: 11 Month: 10 Year: 2013
Print publication date: Year: 2014
Electronic publication date: Day: 6 Month: 1 Year: 2014
Volume: 2014E-location ID: 653543
PubMed Id: 24672794
ID: 3930186
DOI: 10.1155/2014/653543

The Role of Bioactive Lipids in Stem Cell Mobilization and Homing: Novel Therapeutics for Myocardial Ischemia
Yuri M. Klyachkin1
Anush V. Karapetyan1
Mariusz Z. Ratajczak23
Ahmed Abdel-Latif1*
1Gill Heart Institute and Division of Cardiovascular Medicine, University of Kentucky and Lexington VA Medical Center, Lexington, KY 40536-020, USA
2Stem Cell Biology Institute, James Graham Brown Cancer Center, University of Louisville, Louisville, KY 40202, USA
3Department of Physiology, Pomeranian Medical University, Szczecin, Poland
Correspondence: *Ahmed Abdel-Latif:
[other] Academic Editor: Dirk Bandorski

1. Introduction: Ischemic Heart Disease

Ischemic heart disease (IHD), which includes heart failure induced by myocardial infarction (MI), is the single most prevalent cause of morbidity and mortality worldwide. Currently, IHD caused 1 of every 6 deaths in the United States, and despite the significant advancements in medical and revascularization therapies, the prognosis of millions of patients with ischemic heart disease remains poor [1]. IHD results from the partial or complete interruption of oxygenated blood supply to the heart muscle primarily due to an occlusion of a coronary artery. The resulting ischemia causes myocardial cell death and, if left untreated, results in extensive tissue damage. While heart transplantation is a viable therapy to replace the infarcted myocardium it is still plagued by limited availability of donors, peri- and postprocedural complications, side effects of immunosuppressive therapies, and overall less than optimal patient prognosis. Until recently, the notion that MI-damaged myocardium could regenerate was non-existent. This review will examine breakthroughs in cardiac stem cell biology and recent advances in cell-based therapies to treat ischemic myocardium.

2. The Role BM-Derived Cells in Continuous Renewal of Cardiomyocytes

Until a decade ago, it was believed that the human heart was a postmitotic organ that is not capable of self-renewal, and therefore the MI-damaged myocardium could not be regenerated. However, this dogma has been refuted by multiple groups. The study by Quaini et al., investigating the chimerism of sex-mismatched transplanted heart, presented early evidence for myocardial regeneration by demonstrating active renewal of all three major cell lines in human hearts. The number of recipient-originated cardiomyocytes, vascular smooth muscle cells, and endothelial cells increased significantly in hearts from female donors that were transplanted into male recipients. Furthermore, these primitive cells, which originated in the bone marrow (BM), expressed stem cell antigens including c-kit, MDR1, and Sca-1. Interestingly, a fraction of these cells were Y-chromosome-positive, providing direct evidence that these cells translocated from the host to the myocardium of the grafted heart. Moreover, migration of these primitive cell populations to the grafted heart resulted in their loss of stem-cell markers, active proliferation, and acquisition of the mature phenotype followed by cell colonization and de novo formation of myocytes, coronary arterioles, and capillaries [2]. To address the question of BM origin of chimeric myocytes, the follow-up investigation analyzed hearts of patients who have undergone gender-mismatched BM transplantation. The key findings suggested that BM acts as a source of extracardiac progenitor cells contributing to cardiomyocyte formation and accounts for at least part of the cell chimerism observed in other studies. Interestingly, the potential origin and phenotype of marrow myocyte precursors included lineage-restricted mesenchymal, hematopoietic, and multipotent adult progenitor cells [3]. Together, these data established human bone marrow as a source of bone marrow stem/progenitor cells (BMSPCs) capable of de novo cardiomyocyte formation and possibly repair. However, the mechanisms governing the mobilization of BM cells from their niches to the myocardium are poorly understood. The literature suggests that the magnitude of this phenomenon is significant replacing at least half of the adult cardiomyocytes during normal physiological aging [4]. Anversa's group demonstrated higher chimerism with physiological aging and in heart failure [5]. In this study, the human adult heart is capable of replacing its entire population of cardiomyocytes, endothelial cells and fibroblasts 6–8 times during normal life span and under physiological conditions. The chimerism of cardiomyocytes is age dependent and is also influenced with pathological conditions such as heart failure [5] and ischemic injury [6].

Hematopoietic stem/progenitor cells (HSPCs) escape their BM niche in response to chemotactic gradients and can be detected in the PB under steady state conditions [7]. Numerous factors have been shown to be responsible for HSPC mobilization including strenuous exercise [8], tissue, or organ injury (including ischemic cardiac events) [9, 10] and may significantly increase in circulation after administration of pharmacological agents [11, 12]. BMSPCs have multifaceted roles in an adult organism most importantly being involved in lymphohematopoiesis [7] and immune surveillance [13]. Initially, multiple groups have demonstrated that the gradient of chemotactic stromal derived factor-1 (SDF-1) is the major determining factor of BMSPCs' destination [14, 15]. Since BMSPCs express the SDF-1 receptor-CXCR4 and SDF-1 is expressed by osteoblasts and fibroblasts in the BM microenvironment, it is undisputed that the resulting SDF-1-CXCR4 interaction results in BMSPCs' retention in the BM niches [15]. Furthermore, BMSPCs express very late antigen-4 (VLA-4, also known as α4β1-integrin) while the cells in the BM microenvironment express its ligand, vascular adhesion molecule-1 (also known as CD106), and further contribute to BMSPCs BM retention [1618].

Lately, however, the chemokine-exclusive paradigm was challenged by numerous observations supporting SDF-1-CXCR4-independent homing and mobilization of BMSPCs. Specifically, it was shown by numerous groups that the plasma SDF-1 level does not always correlate with mobilization of BMSPCs [1922]. While some studies have observed chemotaxis of BMSPCs to an increased SDF-1 gradient, the SDF-1 was administered at supraphysiological concentrations (100–300 ng/mL) [23, 24], which is about 100 times higher than the SDF-1 concentrations measured in human or murine biological fluids [25]. Also, SDF-1 upregulation was observed in tissues injured by hypoxia, and similar upregulation takes place in the BM microenvironment during conditioning for transplantation by radiochemotherapy or after administration of pharmacological agents that promote mobilization of BMSPCs (such as G-CSF or a CXCR4 antagonist AMD3100) [18, 2628]. Ironically, these conditions induce upregulation of several proteolytic enzymes released by BM cells, such as metalloproteinase 2 (MMP-2), MMP-9, cathepsin G, and neutrophil elastase, thereby proteolytically inactivating SDF-1 and CXCR4 and neutralizing chemotactic activity of SDF-1 towards BMSPCs [26, 29, 30]. It is important to note that this proteolytic environment would promote HSPC mobilization by decreasing SDF-1-CXCR4-mediated retention (as well as attenuating VLA-4-CD106 interaction); however SDF-1 homing would be impaired due to enhanced proteolytic degradation of SDF-1 [18, 26, 31]. Together, these observations imply that other possibly protease-resistant chemoattractants are involved in HSPC mobilization in order to make up for the deficiency of the SDF-1 gradient between the BM and PB. The above findings directed the investigation towards proteolysis-resistant sphingolipids, specifically sphingophospholipids (sphingosine 1-phosphate and ceramide 1-phosphate), which were shown to be potent chemoattractants for BMSPCs.

3. Sphingolipids and Stem Cell Signaling

Sphingolipids are a class of lipids consisting of a backbone composed of sphingoid bases and an amino alcohol sphingosine [32]. Initially, they were believed to be sheathing nerves and the interest in their research remained confined to a small group of scientists. As the evidence for pathophysiological importance of sphingolipids grew, so did their research field. As of today sphingolipids are shown to be involved in a wide variety of biological responses in a diversity of cell types including stimulation of cell proliferation, inhibition of apoptosis, and regulation of cell shape and cell motility [3336].

Sphingolipids are important structural components of cell membranes and are derived from ceramide, the proverbial “core” of sphingolipid metabolism. Ceramide can be deacylated to sphingosine which is then phosphorylated by sphingosine kinases (SPHK1 or SPHK2) to yield sphingosine 1-phosphate (S1P) (Figure 1). Both transcripts of SPHK1 and SPHK2 are subject to alternative splicing resulting in multiple isoforms for each kinase [37]. Transgenic mouse studies have demonstrated partial redundancy of SPHK1 and SPHK2 since SPHK1−/− or SPHK2−/− mice were phenotypically normal while elimination of both genes resulted in embryonic death [38, 39] indicating that S1P is produced exclusively by SPHKs in vivo. Ceramide 1-phosphate (C1P) can be generated by phosphorylation of ceramide (N-acyl sphingosine) by ceramide kinase [40]. Both S1P and C1P have limited half-lives and their levels are kept in check by numerous enzymes. S1P is irreversibly degraded by S1P lyase and is also regulated by lipid phosphate phosphatases (LPP1–3) and S1P-specific phosphatases (SPP1 and SPP2) [4145], and C1P is regulated by LPP1–3 [41, 45]. The major source of plasma S1P are red blood cells, activated platelets, albumin, high-density lipoproteins, and extracellular SPHK1 derived from vascular endothelial cells [33, 46, 47], while the primary contribution to C1P plasma levels comes from intracellular C1P which has been released or “leaked” from damaged cells [48].

Upon their release, both S1P and C1P interact with a variety of G protein-coupled seven-transmembrane receptors. There are 5 S1P receptor subtypes (S1P1–5) that are widely expressed throughout mammalian tissues. S1P4 and S1P5 are expressed and function in the immune and nervous system, respectively, S1P1–3 are most abundant throughout the cardiovascular system and are expressed on BMSPCs. S1P1 is coupled exclusively via Gi to Ras-MAP kinase, phosphoinositide (PI) 3-kinase-Akt pathway and phospholipase C pathway. S1P2 and S1P3 are coupled to multiple G proteins, such as Gq, G12/13 and Gi to activate phospholipase C pathway and Rho pathway [3436, 49]. The signaling cascade activated by S1P binding to either S1P1 or S1P3 is responsible for HSPC migration [13, 50, 51]. Activation of S1P2 and, however, yields an opposite effect, negatively regulating HSPC mobilization [52]. While the receptor for C1P is yet to be identified, its signaling is sensitive to pertussis toxin, thereby implicating a Gi protein coupled receptor [53, 54].

4. Sphingosine 1-Phosphate Chemoattracts BMSPCs

Once S1P receptors were discovered on BMSPCs, they were immediately characterized as G protein-coupled seven-transmembrane receptor thereby placing them in the same class as chemokine receptors. This observation raised one important question: can S1P act as a direct chemoattractant for BMSPCs? Initially, Seitz et al. demonstrated a dose-dependent chemotactic effect of S1P on human HSPCs in a modified Boyden chamber assay [19]. It is possible that polarizing doses of S1P promote signaling through the S1P2 receptor, which in contrast to S1P1, inhibits HSPC chemotaxis [21]. Subsequent studies established that the gradient of S1P between BM and PB is a major determining factor in HSPCs egress. While SDF-1 still has a significant role in HSPCs mobilization, it was demonstrated that plasma derived from normal and mobilized PB strongly chemoattracts murine BM HSPCs independent of plasma SDF-1 levels [21]. This was especially evident when removal of lipids from plasma by charcoal stripping abolished HSPCs chemotaxis but did not affect responsiveness towards SDF-1 [21]. Ratajczak et al. further showed that steady state S1P plasma levels create a gradient favoring HSPCs egress from the BM. As previously described, HSPCs are actively retained in BM via SDF-1-CXCR4 and VLA4-V-CAM1 interactions. Ratajczak et al. corroborated the significance of S1P in HSPCs chemotaxis by demonstrating that disruption of these interactions via CXCR4 antagonist AMD3100 or triggering a proteolytic environment in the BM would release HSPCs form their niches and therefore free them to follow the bioactive lipids' gradient to PB.

Furthermore, Ratajczak et al. showed that a robust innate immune response during G-CSF mobilization is responsible for increased plasma S1P levels. G-CSF is currently the most frequently used mobilizing agent that efficiently mobilizes BMSPCs after a few consecutive daily injections [55]. It has been established that G-CSF triggers complement complex activation which stimulates granulocytes to release proteolytic enzymes, thereby perturbing SDF-1-CXCR4/VLA-4-VCAM1 interactions in BM niches and facilitating HSPCs release [27]. Remarkably, the lasting effect of G-CSF promotes CC activation and formation of the membrane attack complex (MAC) that was shown to interact with erythrocytes [56]. While erythrocytes serve as the major reservoir of S1P in the PB [20, 57], they are highly protected from MAC by CD59 and decay-accelerating factor (DAF) receptors [58]. However, Ratajczak et al. demonstrated that expression of these receptors on erythrocytes does not give complete protection from activated MAC since G-CSF-induced MAC exposure resulted in plasma S1P levels sufficient for HSPCs egress [21].

While it has been established that S1P is responsible for HSPC trafficking, the mechanism to explain this regulation is still under investigation. Recent evidence suggests that SDF-1 and S1P work synergistically to facilitate migration of primitive murine progenitor cells out of the BM [59]. Further in vitro studies on immature human CD34+ cells demonstrated that S1P1 upregulation decreases their chemotactic activity towards SDF-1 due to reduced cell surface expression of CXCR4 suggesting a potential interaction between S1P and SDF-1 [60]. These observations were recently corroborated by Golan et al. showing that short-term inhibition of S1P/S1P1 axis during steady state conditions or during CXCR4 inhibition (via AMD3100 administration) caused reduction of SDF-1 in the plasma [61]. Interestingly, generation of reactive oxygen species (ROS) via S1P1 signaling were also implicated in HSPCs mobilization through the release of SDF-1 [62]. Since previous studies showed that ROS inhibition reduces SDF-1 secretion during AMD3100-induced mobilization [63], it was hypothesized that ROS signaling might also contribute to SDF-1 secretion. Indeed it was demonstrated that ROS signaling induced SDF-1 secretion thereby facilitating HSPCs egress [61].

S1P-SDF-1 interaction in HSPCs egress was further demonstrated with the help of FTY720, a potent S1P1 desensitizing agent which causes S1P receptor internalization [64]. Interestingly, administration of FTY720 for 24 hours resulted in increased plasma SDF-1 levels but had no effect on HSPCs egress. FTY720 treatment did reduce BM ROS signaling, due to S1P1 downregulation, again pointing out the requirement of S1P1 signaling in HSPC egress. Furthermore, mice that were treated with BM-specific S1P lyase inhibitor 4-deoxypyridoxine (DOP) [44] had increased BM ROS levels and decreased HSPC egress [61]. Together, these observations suggest that the increased concentrations of S1P and SDF-1 in the BM negatively affect HSPC egress, further highlighting the fact that both S1P and SDF-1 levels must be tightly regulated for balanced HSPCs mobilization.

While bioactive lipids such as S1P and C1P are powerful mobilizers of BMSPCs, their role in BMSPCs' mobilization and homing to ischemic myocardium is not well understood. The role of other chemoattractants in BMSPCs homing to a hostile environment such as the infarcted myocardium is also unclear. We recently examined the role of bioactive lipids, complement, and antimicrobial peptides in BMSPC homing during MI. Our data shows elevated level of S1P and C1P in the plasma of MI patients shortly after the onset of MI [65]. Increased S1P and C1P levels were correlated with elevated numbers of circulating BMSPCs suggesting a role of bioactive lipids in BMSPCs mobilization post-MI [65]. Our speculations were corroborated by a modified Boyden chamber assay (chemotaxis assay) where we observed increased BMSPCs' chemotaxis towards plasma isolated from patients at peak BMSPCs mobilization. Moreover, this migration was selectively blocked by VPC23019, a specific S1P1 antagonist, further implicating S1P as a potent BMSPCs chemoattractant during MI [65]. As previously described, MI induces a potent proteolytic environment in which numerous enzymes such as metalloproteinases and proteases irreversibly degrade potent BMSPCs chemoattractants such as SDF-1. Recent evidence suggests a role for antimicrobial protein cathelicidin LL-37 in sensitizing BMSPCs towards significantly lower levels of SDF-1 [66]. LL-37 sensitizes BMSPCs by incorporating CXCR4 into the lipid rafts thereby augmenting CXCR4 signaling. Most importantly, we observed LL-37 overexpression following MI in cardiac tissues as well as cardiac fibroblasts. Furthermore, we implemented the chemotaxis assay to confirm that priming BMSPCs with LL-37 from patients with MI increases their mobilization to low, yet physiological, levels of SDF-1 (2 ng/mL) [65]. Taken together, our findings highlight the importance of bioactive lipids and innate immunity in the mobilization and homing of BMSPCs to the ischemic myocardium (Figure 2).

5. Mobilization of BMSPC Populations during MI

The BM cell populations commonly referred to as BMSPCs is a heterogeneous population of cells consisting of hematopoietic stem cells (HSCs), endothelial progenitor cells (EPCs), mesenchymal stromal cells (MSCs), and pluripotent very small embryonic-like cells (VSELs). Acute myocardial infarction (MI) initiates a systemic inflammatory response that stimulates a signaling cascade that results in egress of BMSPCs from the BM. At the onset of MI, BMSPSs are mobilized following the gradient of a multitude of previously described chemoattractants, including bioactive phospholipids, kinins, chemokines, cytokines, growth factors, and the complement cascade [6772]. Several studies have demonstrated the chimerism of cardiomyocytes, a process that is maintained, at least in part, by BM-derived stem cells [2, 3, 73, 74]. Innate cardiomyocyte renewal is an effective process that replaces up to 45% of the adult cardiomyocytes during the normal lifespan [4] suggesting that development of cardiac cell based therapies is feasible and essential to treat MI-damaged myocardium. The heterogeneity of the BM cell populations could be responsible for the differential response to the multitude of chemoattractants.

6. Fate of Adults Stem Cells after MI
6.1. Biology of Infarcted Myocardium

However, the question still remains what is the fate of BMSPCs once they reach the ischemic myocardium? The fate of BMSPCs is ultimately determined by the nature of the myocardial microenvironment. The onset of ischemic injury and subsequent reperfusion results in a robust proinflammatory state with elevated levels of locally activated complement [7577] and ROS [78]. The induction of ROS and subsequent cytokine cascade contributes to rapid neutrophil infiltration of the infarct region, with neutrophil levels peaking between 24 and 72 hours after MI [76, 79, 80]. Furthermore, neutrophils attracted to the ischemic myocardium release proteolytic enzymes and additional ROS which may cause collateral damage to the infiltrating stem cells. It is clear that the above described mechanisms as well as the lack of a good blood supply to the infarct region make the myocardial microenvironment early on post-MI unsuitable for stem cell arrival. However, as soon as 5 days after MI the acute inflammatory response subsides, and angiogenesis, the major factor in infarct healing, begins to take place [81, 82]. Thus, around this time, when the acute inflammatory response has decreased and the infarct site is being vascularized, stem cells might find the right environment to attach and proliferate. This window of opportunity is limited, however, due to evidence of extensive scar formation as soon as 2 weeks after MI, which would hinder stem cell nesting [8284]. Clinical studies' findings are in agreement with these pathological findings and temporal trends. REPAIR-AMI study demonstrated that the beneficial effects of BM derived mononuclear cells were most evident when the cells were transplanted ≥5 days after the acute myocardial injury [85].

6.2. Therapeutic Effects of Adult Stem Cells after MI

Once the stem cells do survive their journey to the infarcted myocardium after MI, their ultimate contribution to myocardial repair is still unclear. Since adult myocardium has very limited potential for self-regeneration, the stem cells may contribute to ischemic myocardium repair via various paracrine mechanisms or differentiation into endothelium and/or cardiomyocytes. There is ample evidence supporting the hypothesis that paracrine mechanisms mediated by factors released by the adult stem cells play an essential role in myocardial repair after stem cell mobilization following MI. Numerous groups have shown that adult stem cells, and especially mesenchymal stem cells (MSCs; described above), secrete a broad range of chemokines, cytokines, and growth factors that are potentially involved in cardiac repair [86]. Interestingly, hypoxia at the site of injury in conjunction with stem cell administration further stimulates production of these factors which includes hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), insulin-like growth factor (IGF)-I, basic fibroblast growth factor (bFGF), and adrenomedullin [87, 88]. The paracrine benefits were further corroborated by administering conditioned medium (CM) from adult stem cells and comparing those effects to actual stem cell therapy [8991]. These paracrine effects of BM derived cells extend to other populations such as cKit+ cells and VSELs, thereby contributing to regeneration of ischemic myocardium [92]. The authors demonstrated that the improvement in cardiac functions were disproportionate to the rate of differentiation of BM derived cells suggesting that various factors secreted by these cells can explain the majority of beneficial effects. We observed similar findings with VSELs in an animal model of acute ischemic injury [93].

Differentiation of adult stem cells into cardiomyocytes and their subsequent contribution to post-MI repair has been extensively investigated for more than a decade. Initial in vitro studies were able to isolate adult stem cells from either BM or adipose tissue and through various culture conditions, induce their differentiation into beating cells exhibiting cardiomyocyte morphology and physiology [94103]. Although recent in vivo studies have revealed that heart cells are generated in adult mammals during normal homeostasis as well as post-MI, the frequency of generation and the source of new heart cells remain unclear. Some studies suggest a high rate of stem cell differentiation into cardiomyocytes [104]. Other studies suggest that new cardiomyocytes are derived from the division of preexisting cardiomyocytes at a very slow rate [4, 105, 106]. Most recently Senyo et al. showed that the genesis of cardiomyocytes occurs at a low rate by the division of preexisting cardiomyocytes during normal ageing and this process was markedly increased in areas adjacent to myocardial injury [107]. However, the evidence presented herein accents the fact that adult stem cells contribute to myocardial repair by a wide array of effects including paracrine mechanisms, differentiating into functional tissues (cardiac or endothelial), as well as other diverse therapeutic features, to preserve yet undamaged cells and contribute to endogenous creation of new functional tissue.

6.3. The Role of S1P in Adult Stem Cell Differentiation

While evidence suggests that S1P is involved in BMSPC mobilization, the possibility still remains that bioactive lipid signaling may contribute to the ultimate fate of BMSPCs post-MI.

Since S1P is a potent intracellular second messenger it has been implicated in numerous physiological processes including vasculogenesis. Interestingly, recent evidence has also demonstrated that S1P has promoted embryonic and neural stem cell differentiation, proliferation, and maintenance [108110]. Recently, Zhao et al. demonstrated that S1P drove differentiation of human umbilical mesenchymal stem cells (HUMSCs) into cells exhibiting cardiomyocyte-like morphology and physiology, and ultimately the formation of cell sheets from HUMSCs derived cardiomyocytes [111]. This study was the first of its kind to demonstrate that S1P potentiates differentiation of HUMSCs towards functional cardiomyocytes. Furthermore, the engineered cell sheets provide potential for generating clinically applicable myocardial tissues. These newly discovered therapeutic effects of S1P prompted us to extend the work of Zhao et al. by assessing the ability of S1P to initiate differentiation of BMSPCs into cardiomyocytes and vascular cells. Indeed, incubation of BMSPCs with 250 nM of S1P resulted in initiation of cardiac and endothelial expression after 48 hours in cell culture. Figure 3 demonstrates the increased expression of cardiac transcription factors (Nkx-2.5 and GATA4) as well as endothelial genes (vWF and VE-cadherin). Following our results indicating the increased expression of early cardiac and endothelial genes with S1P incubation, we proceeded with examining the expression of functional cardiac and endothelial proteins in BMSPCs cultured for 3-4 weeks in medium supplemented with 250 nM of S1P. BMSPCs expressed morphology suggestive of both cardiac (elongated) and endothelial (rounded) at 4 weeks of culture (Figure 4). Immunohistochemical examination revealed the expression of various cardiac proteins such as troponin and cardiac specific myosin heavy chain in the elongated cells. These proteins were expressed in the cytoplasm (Figures 4(b) and 4(c)). We also observed remnants of cardiac transcription factors such as Nkx-2.5 and GATA4 around the nucleus (Figures 4(a) and 4(c)). Similarly, rounded cells with endothelial morphology were found to have endothelial proteins such as vWF, VE-cadherin, PDGFrα, and PDGFrβ in the cytoplasm suggestive of endothelial lineage differentiation (Figure 4(d)). In parallel, BMSPCs exposed to S1P demonstrated functional endothelial lineage commitment as demonstrated by 10-fold higher tube formation in matrigel assays (P < 0.05) (Figures 4(e) and 4(f)). Taken together, our results suggests that S1P may play a role in the differentiation of BM-derived stem cells. This is of clinical importance given our recent findings that confirm the elevation of S1P level in the plasma and its potential role in BMSPCs mobilization following acute myocardial infarction [65]. We propose that following myocardial infarction and the role of S1P is twofold: mobilization of BMSPCs from their BM niches as well as promoting their subsequent differentiation into myocardial and endothelial lineages thereby further aiding in myocardial repair following ischemic injury (Figure 5).

Multiple new therapies that modulate the plasma levels of S1P or its receptors' expression are approved by the FDA and can be utilized in improving the mobilization and differentiation of BMSPCs in myocardial ischemia in future myocardial regenerative studies. Similarly, priming BM-derived cells with LL-37 can be used to improve their homing to the ischemic myocardium and thus overcome a major hurdle in stem cell regenerative myocardial therapies. We are currently examining both strategies in our laboratory to improve the mobilization and homing of BMSPCs to the ischemic myocardium.

7. Conclusion

The emergence of bioactive lipids (S1P and C1P) as significant players in the trafficking of BMSPCs has added a new dimension to our understanding of BMSPC biology. Available literature and our findings highlight the importance of bioactive lipids in the mobilization and homing of BMSPCs to the ischemic myocardium. In conjunction with our data about their role in stem cell mobilization and homing, it appears that bioactive lipids have an additional role in promoting BMSPC differentiation and proliferation towards cardiac or endothelial tissue lineage. The field of stem cell-based myocardial regeneration still faces multiple challenges such as the appropriate stem cell population, timing of therapy, and the route of administration. Numerous strategies are currently being explored to improve stem cell delivery and retention to the ischemic myocardium following acute injury and in the setting of chronic ischemic heart disease. Our and others recent data provide evidence that innate immunity (cathelicidins and the complement cascade) contribute to BMSPC homing by modulating the sensitivity of BMSPC surface receptors, specifically CXCR4. Therefore, future studies utilizing those, and similar, agents can improve the yield of stem cell therapy in patients who are in dire need for regenerative therapies.


Drs. Abdel-Latif, Karapetyan, and Klyachkin are supported by the University of Kentucky Clinical and Translational Science Pilot Award (UL1TR000117). Dr. Abdel-Latif is supported by the UK College of Medicine Physician Scientist-Clinical Scholar Program and the COBRE funds (P20 GM103527). Dr. Ratajczak is supported by NIH Grant 2R01 DK074720, NIH Grant 1R01HL112788, the Stella and Henry Hoenig Endowment, and Grant Maestro 2011/02/A/NZ4/00035 to Mariusz Z. Ratajczak.

Conflict of Interests

None of the authors have any financial or other conflict of interests to report in relations to this manuscript or any of the included work.

1. Roger VL,Go AS,Lloyd-Jones DM,et al. Heart disease and stroke statistics—2011 update: a report from the American Heart AssociationCirculationYear: 20111234e18e20921160056
2. Quaini F,Urbanek K,Beltrami AP,et al. Chimerism of the transplanted heartThe New England Journal of MedicineYear: 200234615152-s2.0-003701213911777997
3. Deb A,Wang S,Skelding KA,Miller D,Simper D,Caplice NM. Bone marrow-derived cardiomyocytes are present in adult human heart: a study of gender-mismatched bone marrow transplantation patientsCirculationYear: 20031079124712492-s2.0-003743229712628942
4. Bergmann O,Bhardwaj RD,Bernard S,et al. Evidence for cardiomyocyte renewal in humansScienceYear: 20093245923981022-s2.0-6424910705919342590
5. Kajstura J,Rota M,Cappetta D,et al. Cardiomyogenesis in the aging and failing human heartCirculationYear: 2012126151869188122955965
6. Hsieh PCH,Segers VFM,Davis ME,et al. Evidence from a genetic fate-mapping study that stem cells refresh adult mammalian cardiomyocytes after injuryNature MedicineYear: 20071389709742-s2.0-34547699399
7. Bonig H,Priestley GV,Oehler V,Papayannopoulou T. Hematopoietic progenitor cells (HPC) from mobilized peripheral blood display enhanced migration and marrow homing compared to steady-state bone marrow HPCExperimental HematologyYear: 20073523263342-s2.0-3384637441117258081
8. Möbius-Winkler S,Hilberg T,Menzel K,et al. Time-dependent mobilization of circulating progenitor cells during strenuous exercise in healthy individualsJournal of Applied PhysiologyYear: 20091076194319502-s2.0-7344912037419797690
9. Wojakowski W,Tendera M. Mobilization of bone marrow-derived progenitor cells in acute coronary syndromesFolia Histochemica et CytobiologicaYear: 20054342292322-s2.0-2774448501616382890
10. Wojakowski W,Landmesser U,Bachowski R,Jadczyk T,Tendera M. Mobilization of stem and progenitor cells in cardiovascular diseasesLeukemiaYear: 201226123332-s2.0-8485670838821788948
11. Paczkowska E,Kucia M,Koziarska D,et al. Clinical evidence that very small embryonic-like stem cells are mobilized into peripheral blood in patients after strokeStrokeYear: 2009404123712442-s2.0-6524915240519246697
12. Lee HM,Wysoczynski M,Liu R,et al. Mobilization studies in complement-deficient mice reveal that optimal AMD3100 mobilization of hematopoietic stem cells depends on complement cascade activation by AMD3100-stimulated granulocytesLeukemiaYear: 20102435735822-s2.0-7794942473120033053
13. Massberg S,Schaerli P,Knezevic-Maramica I,et al. Immunosurveillance by hematopoietic progenitor cells trafficking through blood, lymph, and peripheral tissuesCellYear: 2007131599410082-s2.0-3624895706318045540
14. Wright DE,Bowman EP,Wagers AJ,Butcher EC,Weissman IL. Hematopoietic stem cells are uniquely selective in their migratory response to chemokinesJournal of Experimental MedicineYear: 20021959114511542-s2.0-003702965411994419
15. Lapidot T,Dar A,Kollet O. How do stem cells find their way home?BloodYear: 20051066190119102-s2.0-2324443546715890683
16. Peled A,Grabovsky V,Habler L,et al. The chemokine SDF-1 stimulates integrin-mediated arrest of CD34+ cells on vascular endothelium under shear flowJournal of Clinical InvestigationYear: 19991049119912112-s2.0-003269874710545519
17. Lévesque J-P,Takamatsu Y,Nilsson SK,Haylock DN,Simmons PJ. Vascular cell adhesion molecule-1 (CD106) is cleaved by neutrophil proteases in the bone marrow following hematopoietic progenitor cell mobilization by granulocyte colony-stimulating factorBloodYear: 2001985128912972-s2.0-003546985311520773
18. Lévesque J-P,Hendy J,Takamatsu Y,Simmons PJ,Bendall LJ. Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by gcsf or cyclophosphamideJournal of Clinical InvestigationYear: 200311121871962-s2.0-003723764812531874
19. Seitz G,Boehmler AM,Kanz L,Möhle R. The role of sphingosine 1-phosphate receptors in the trafficking of hematopoietic progenitor cellsAnnals of the New York Academy of SciencesYear: 2005104484892-s2.0-2204444405615958700
20. Hänel P,Andréani P,Gräler MH. Erythrocytes store and release sphingosine 1-phosphate in bloodThe FASEB JournalYear: 2007214120212092-s2.0-33947634013
21. Ratajczak MZ,Lee H,Wysoczynski M,et al. Novel insight into stem cell mobilization-Plasma sphingosine-1-phosphate is a major chemoattractant that directs the egress of hematopoietic stem progenitor cells from the bone marrow and its level in peripheral blood increases during mobilization due to activation of complement cascade/membrane attack complexLeukemiaYear: 20102459769852-s2.0-7795242275720357827
22. Marquez-Curtis LA,Turner AR,Sridharan S,Ratajczak MZ,Janowska-Wieczorek A. The ins and outs of hematopoietic stem cells: studies to improve transplantation outcomesStem Cell Reviews and ReportsYear: 2011735906072-s2.0-7996031554821140298
23. Christopherson KW II,Hangoc G,Mantel CR,Broxmeyer HE. Modulation of hematopoietic stem cell homing and engraftment by CD26ScienceYear: 20043055686100010032-s2.0-404311776915310902
24. Basu S,Ray NT,Atkinson SJ,Broxmeyer HE. Protein phosphatase 2A plays an important role in stromal cell-derived factor-1/CXC chemokine ligand 12-mediated migration and adhesion of CD34 + cellsJournal of ImmunologyYear: 20071795307530852-s2.0-36148969861
25. Gazitt Y,Liu Q. Plasma levels of SDF-1 and expression of SDF-1 receptor on CD34+ cells in mobilized peripheral blood of non-Hodgkin’s lymphoma patientsStem CellsYear: 200119137452-s2.0-003518658511209089
26. Kim CH,Wu W,Wysoczynski M,et al. Conditioning for hematopoietic transplantation activates the complement cascade and induces a proteolytic environment in bone marrow: a novel role for bioactive lipids and soluble C5b-C9 as homing factorsLeukemiaYear: 20122611061162-s2.0-8485671325221769103
27. Greenbaum AM,Link DC. Mechanisms of G-CSF-mediated hematopoietic stem and progenitor mobilizationLeukemiaYear: 20112522112172-s2.0-7975153253221079612
28. Pusic I,Dipersio JF. Update on clinical experience with AMD3100, an SDF-1/CXCL12-CXCR4 inhibitor, in mobilization of hematopoietic stem and progenitor cellsCurrent Opinion in HematologyYear: 20101743193262-s2.0-7795408629220473162
29. McQuibban GA,Butler GS,Gong J-H,et al. Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1The Journal of Biological ChemistryYear: 20012764743503435082-s2.0-003594135911571304
30. Angus McQuibban G,Gong J-H,Wong JP,Wallace JL,Clark-Lewis I,Overall CM. Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivoBloodYear: 20021004116011672-s2.0-003710318312149192
31. Pelus LM,Bian H,King AG,Fukuda S. Neutrophil-derived MMP-9 mediates synergistic mobilization of hematopoietic stem and progenitor cells by the combination of G-CSF and the chemokines GROβ/CXCL2 and GROβT/CXCL2Δ4BloodYear: 200410311101192-s2.0-034822769712958067
32. Merrill AH Jr.,Schmelz E-M,Dillehay DL,et al. Sphingolipids—the enigmatic lipid class: biochemistry, physiology and pathophysiologyToxicology and Applied PharmacologyYear: 199714212082252-s2.0-00310318599007051
33. Yatomi Y,Ozaki Y,Ohmori T,Igarashi Y. Sphingosine 1-phosphate: synthesis and releaseProstaglandins and Other Lipid MediatorsYear: 2001641–41071222-s2.0-003500588711324700
34. Takuwa Y. Subtype-specific differential regulation of Rho family G proteins and cell migration by the Edg family sphingosine-1-phosphate receptorsBiochimica et Biophysica ActaYear: 200215821–31121202-s2.0-003716206412069818
35. Spiegel S,Milstien S. Sphingosine-1-phosphate: an enigmatic signalling lipidNature Reviews Molecular Cell BiologyYear: 2003453974072-s2.0-0038218405
36. Hla T. Physiological and pathological actions of sphingosine 1-phosphateSeminars in Cell and Developmental BiologyYear: 20041555135202-s2.0-324269673015271296
37. Alemany R,Van Koppen CJ,Danneberg K,Ter Braak M,Meyer Zu Heringdorf D. Regulation and functional roles of sphingosine kinasesNaunyn-Schmiedeberg’s Archives of PharmacologyYear: 20073745-64134282-s2.0-33846811196
38. Allende ML,Sasaki T,Kawai H,et al. Mice deficient in sphingosine kinase 1 are rendered lymphopenic by FTY720The Journal of Biological ChemistryYear: 20042795052487524922-s2.0-1064426024315459201
39. Mizugishi K,Yamashita T,Olivera A,Miller GF,Spiegel S,Proia RL. Essential role for sphingosine kinases in neural and vascular developmentMolecular and Cellular BiologyYear: 2005252411113111212-s2.0-2854443747816314531
40. Boath A,Graf C,Lidome E,Ullrich T,Nussbaumer P,Bornancin F. Regulation and traffic of ceramide 1-phosphate produced by ceramide kinase: comparative analysis to glucosylceramide and sphingomyelinThe Journal of Biological ChemistryYear: 200828313851785262-s2.0-4374910538018086664
41. Sciorra VA,Morris AJ. Roles for lipid phosphate phosphatases in regulation of cellular signalingBiochimica et Biophysica ActaYear: 200215821–345512-s2.0-003716209112069809
42. Long J,Darroch P,Wan KF,et al. Regulation of cell survival by lipid phosphate phosphatases involves the modulation of intracellular phosphatidic acid and sphingosine 1-phosphate poolsBiochemical JournalYear: 2005391, part 125322-s2.0-2684444254715960610
43. Mechtcheriakova D,Wlachos A,Sobanov J,et al. Sphingosine 1-phosphate phosphatase 2 is induced during inflammatory responsesCellular SignallingYear: 20071947487602-s2.0-3384705546717113265
44. Schwab SR,Pereira JP,Matloubian M,Xu Y,Huang Y,Cyster JG. Immunology: lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradientsScienceYear: 20053095741173517392-s2.0-2464446950216151014
45. Brindley DN,English D,Pilquil C,Buri K,Ling Z-C. Lipid phosphate phosphatases regulate signal transduction through glycerolipids and sphingolipidsBiochimica et Biophysica ActaYear: 200215821–333442-s2.0-003716206112069808
46. Kihara A,Igarashi Y. Production and release of sphingosine 1-phosphate and the phosphorylated form of the immunomodulator FTY720Biochimica et Biophysica ActaYear: 2008178194965022-s2.0-4994910971318555808
47. Venkataraman K,Thangada S,Michaud J,et al. Extracellular export of sphingosine kinase-1a contributes to the vascular S1P gradientBiochemical JournalYear: 200639734614712-s2.0-3374689767716623665
48. Lamour NF,Stahelin RV,Wijesinghe DS,et al. Ceramide kinase uses ceramide provided by ceramide transport protein: localization to organelles of eicosanoid synthesisJournal of Lipid ResearchYear: 2007486129313012-s2.0-3454817709817392267
49. Ishii I,Fukushima N,Ye X,Chun J. Lysophospholipid receptors: signaling and biologyAnnual Review of BiochemistryYear: 2004733213542-s2.0-2142851264
50. Jo E,Sanna MG,Gonzalez-Cabrera PJ,et al. S1P1-selective in vivo-active agonists from high-throughput screening: off-the-shelf chemical probes of receptor interactions, signaling, and fateChemistry and BiologyYear: 20051267037152-s2.0-2494453583315975516
51. Walter DH,Rochwalsky U,Reinhold J,et al. Sphingosine-1-phosphate stimulates the functional capacity of progenitor cells by activation of the CXCR4-dependent signaling pathway via the S1P3 receptorArteriosclerosis, Thrombosis, and Vascular BiologyYear: 20072722752822-s2.0-33846413190
52. Michaud J,Im D-S,Hla T. Inhibitory role of sphingosine 1-phosphate receptor 2 in macrophage recruitment during inflammationJournal of ImmunologyYear: 20101843147514832-s2.0-77949332336
53. Gómez-Muñoz A,Kong JY,Salh B,Steinbrecher UP. Ceramide-1-phosphate blocks apoptosis through inhibition of acid sphingomyelinase in macrophagesJournal of Lipid ResearchYear: 2004451991052-s2.0-084228298314523050
54. Granado MH,Gangoiti P,Ouro A,et al. Ceramide 1-phosphate (C1P) promotes cell migration. Involvement of a specific C1P receptorCellular SignallingYear: 20092134054122-s2.0-5824912992519041940
55. Ryan MA,Nattamai KJ,Xing E,et al. Pharmacological inhibition of EGFR signaling enhances G-CSF-induced hematopoietic stem cell mobilizationNature MedicineYear: 20101610114111462-s2.0-77957762029
56. Lindorfer MA,Pawluczkowycz AW,Peek EM,Hickman K,Taylor RP,Parker CJ. A novel approach to preventing the hemolysis of paroxysmal nocturnal hemoglobinuria: both complement-mediated cytolysis and C3 deposition are blocked by a monoclonal antibody specific for the alternative pathway of complementBloodYear: 201011511228322912-s2.0-7795038022120068220
57. Ohkawa R,Nakamura K,Okubo S,et al. Plasma sphingosine-1-phosphate measurement in healthy subjects: close correlation with red blood cell parametersAnnals of Clinical BiochemistryYear: 200845, part 43563632-s2.0-4774909929618583619
58. Bessler M,Hiken J. The pathophysiology of disease in patients with paroxysmal nocturnal hemoglobinuriaHematologyYear: 200820081041102-s2.0-6765118104719074066
59. Whetton AD,Lu Y,Pierce A,Carney L,Spooncer E. Lysophospholipids synergistically promote primitive hematopoietic cell chemotaxis via a mechanism involving Vav 1BloodYear: 20031028279828022-s2.0-014192391212829605
60. Ryser MF,Ugarte F,Lehmann R,Bornhäuser M,Brenner S. S1P1 overexpression stimulates S1P-dependent chemotaxis of human CD34+ hematopoietic progenitor cells but strongly inhibits SDF-1/CXCR4-dependent migration and in vivo homingMolecular ImmunologyYear: 20084611661712-s2.0-5294913517518760838
61. Golan K,Vagima Y,Ludin A,et al. S1P promotes murine progenitor cell egress and mobilization via S1P1-mediated ROS signaling and SDF-1 releaseBloodYear: 201211911247824882-s2.0-8485866880422279055
62. Tesio M,Golan K,Corso S,et al. Enhanced c-Met activity promotes G-CSF-induced mobilization of hematopoietic progenitor cells via ROS signalingBloodYear: 201111724194282-s2.0-7875156501720585044
63. Dar A,Schajnovitz A,Lapid K,et al. Rapid mobilization of hematopoietic progenitors by AMD3100 and catecholamines is mediated by CXCR4-dependent SDF-1 release from bone marrow stromal cellsLeukemiaYear: 2011258128612962-s2.0-8005179696521494253
64. Brinkmann V. FTY720: mechanism of action and potential benefit in organ transplantationYonsei Medical JournalYear: 20044569919972-s2.0-1234430230615627289
65. Karapetyan AV,Klyachkin YM,Selim S,et al. Bioactive lipids and cationic antimicrobial peptides as new potential regulators for trafficking of bone marrow-derived stem cells in patients with acute myocardial infarctionStem Cells and DevelopmentYear: 20132211
66. Wu W,Kim CH,Liu R,et al. The bone marrow-expressed antimicrobial cationic peptide LL-37 enhances the responsiveness of hematopoietic stem progenitor cells to an SDF-1 gradient and accelerates their engraftment after transplantationLeukemiaYear: 20122647367452-s2.0-8485964053421931324
67. Kucia M,Dawn B,Hunt G,et al. Cells expressing early cardiac markers reside in the bone marrow and are mobilized into the peripheral blood after myocardial infarctionCirculation ResearchYear: 20049512119111992-s2.0-1064422114515550692
68. Massa M,Rosti V,Ferrario M,et al. Increased circulating hematopoietic and endothelial progenitor cells in the early phase of acute myocardial infarctionBloodYear: 200510511992062-s2.0-1994442717915345590
69. Shintani S,Murohara T,Ikeda H,et al. Mobilization of endothelial progenitor cells in patients with acute myocardial infarctionCirculationYear: 200110323277627792-s2.0-003584958811401930
70. Wojakowski W,Tendera M,Kucia M,et al. Mobilization of bone marrow-derived Oct-4+ SSEA-4+ very small embryonic-like stem cells in patients with acute myocardial infarctionJournal of the American College of CardiologyYear: 2009531192-s2.0-5784916947219118716
71. Wojakowski W,Tendera M,Zebzda A,et al. Mobilization of CD34+, CD117+, CXCR4+, c-met+ stem cells is correlated with left ventricular ejection fraction and plasma NT-proBNP levels in patients with acute myocardial infarctionEuropean Heart JournalYear: 20062732832892-s2.0-3074447163616267071
72. Vandervelde S,Van Luyn MJA,Tio RA,Harmsen MC. Signaling factors in stem cell-mediated repair of infarcted myocardiumJournal of Molecular and Cellular CardiologyYear: 20053923633762-s2.0-2224449292915992820
73. de Weger RA,Verbrugge I,Bruggink AH,et al. Stem cell-derived cardiomyocytes after bone marrow and heart transplantationBone Marrow TransplantationYear: 20084165635692-s2.0-4154909368818037937
74. Rupp S,Koyanagi M,Iwasaki M,et al. Characterization of long-term endogenous cardiac repair in children after heart transplantationEuropean Heart JournalYear: 20082915186718722-s2.0-4874911766718511408
75. Wilde WS,Hill JH,Wilson E,Schielke GP. Exchange of free and albumin-bound Evans blue in interstitium of hamster kidneyThe American Journal of PhysiologyYear: 19712206199119992-s2.0-00150807535087851
76. Dreyer WJ,Michael LH,Nguyen T,et al. Kinetics of C5a release in cardiac lymph of dogs experiencing coronary artery ischemia-reperfusion injuryCirculation ResearchYear: 1992716151815242-s2.0-00264901821423944
77. Ivey CL,Williams FM,Collins PD,Jose PJ,Williams TJ. Neutrophil chemoattractants generated in two phases during reperfusion of ischemic myocardium in the rabbit. Evidence for a role for C5a and interleukin-8Journal of Clinical InvestigationYear: 1995956272027282-s2.0-00290708077769111
78. Patel KD,Zimmerman GA,Prescott SM,McEver RP,McIntyre TM. Oxygen radicals induce human endothelial cells to express GMP-140 and bind neutrophilsJournal of Cell BiologyYear: 199111247497592-s2.0-00260599291704376
79. Frangogiannis NG,Lindsey ML,Michael LH,et al. Resident cardiac mast cells degranulate and release preformed TNF-α, initiating the cytokine cascade in experimental canine myocardial ischemia/reperfusionCirculationYear: 19989876997102-s2.0-00325442019715863
80. Virag JI,Murry CE. Myofibroblast and endothelial cell proliferation during murine myocardial infarct repairAmerican Journal of PathologyYear: 20031636243324402-s2.0-034527594314633615
81. Sun Y,Weber KT. Infarct scar: a dynamic tissueCardiovascular ResearchYear: 20004622502562-s2.0-003407437110773228
82. Li R-K,Mickle DAG,Weisel RD,Rao V,Jia Z-Q. Optimal time for cardiomyocyte transplantation to maximize myocardial function after left ventricular injuryAnnals of Thoracic SurgeryYear: 2001726195719632-s2.0-003566577111789777
83. Hu X,Wang J,Chen J,et al. Optimal temporal delivery of bone marrow mesenchymal stem cells in rats with myocardial infarctionEuropean Journal of Cardio-thoracic SurgeryYear: 20073134384432-s2.0-3384730201017239611
84. Jiang C-Y,Gui C,He A-N,et al. Optimal time for mesenchymal stem cell transplantation in rats with myocardial infarctionScience BYear: 2008986306372-s2.0-4874910249518763313
85. Schächinger V,Erbs S,Elsässer A,et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial in acute myocardial InfarctionThe New England Journal of MedicineYear: 2006355121210122116990384
86. Caplan AI,Dennis JE. Mesenchymal stem cells as trophic mediatorsJournal of Cellular BiochemistryYear: 2006985107610842-s2.0-3374642437316619257
87. Yoon Y-S,Wecker A,Heyd L,et al. Clonally expanded novel multipotent stem cells from human bone marrow regenerate myocardium after myocardial infarctionJournal of Clinical InvestigationYear: 200511523263382-s2.0-2014436257615690083
88. Nagaya N,Kangawa K,Itoh T,et al. Transplantation of mesenchymal stem cells improves cardiac function in a rat model of dilated cardiomyopathyCirculationYear: 20051128112811352-s2.0-2404453509216103243
89. Gnecchi M,He H,Liang OD,et al. Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cellsNature MedicineYear: 20051143673682-s2.0-20244389882
90. Gnecchi M,He H,Noiseux N,et al. Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvementThe FASEB JournalYear: 20062066616692-s2.0-33646252939
91. Takahashi M,Li T-S,Suzuki R,et al. Cytokines produced by bone marrow cells can contribute to functional improvement of the infarcted heart by protecting cardiomyocytes from ischemic injuryAmerican Journal of Physiology: Heart and Circulatory PhysiologyYear: 20062912H886H8932-s2.0-3374683689116603697
92. Loffredo FS,Steinhauser ML,Gannon J,Lee RT. Bone marrow-derived cell therapy stimulates endogenous cardiomyocyte progenitors and promotes cardiac repairCell Stem CellYear: 2011843893982-s2.0-7995390308321474103
93. Dawn B,Tiwari S,Kucia MJ,et al. Transplantation of bone marrow-derived very small embryonic-like stem cells attenuates left ventricular dysfunction and remodeling after myocardial infarctionStem CellsYear: 2008266164616552-s2.0-4864910437318420834
94. Condorelli G,Borello U,De Angelis L,et al. Cardiomyocytes induce endothelial cells to trans-differentiate into cardiac muscle: implications for myocardium regenerationProceedings of the National Academy of Sciences of the United States of AmericaYear: 2001981910733107382-s2.0-003584553011535818
95. Jackson KA,Majka SM,Wang H,et al. Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cellsJournal of Clinical InvestigationYear: 200110711139514022-s2.0-003498849111390421
96. Grounds MD,White JD,Rosenthal N,Bogoyevitch MA. The role of stem cells in skeletal and cardiac muscle repairJournal of Histochemistry and CytochemistryYear: 20025055896102-s2.0-003623897011967271
97. Makino S,Fukuda K,Miyoshi S,et al. Cardiomyocytes can be generated from marrow stromal cells in vitroJournal of Clinical InvestigationYear: 199910356977052-s2.0-003310638410074487
98. Orlic D,Kajstura J,Chimenti S,et al. Bone marrow cells regenerate infarcted myocardiumNatureYear: 200141068297017052-s2.0-003581024011287958
99. Gepstein L. Derivation and potential applications of human embryonic stem cellsCirculation ResearchYear: 200291108668762-s2.0-003711255912433831
100. Zuk PA,Zhu M,Mizuno H,et al. Multilineage cells from human adipose tissue: implications for cell-based therapiesTissue EngineeringYear: 2001722112282-s2.0-003506753911304456
101. Erickson GR,Gimble JM,Franklin DM,Rice HE,Awad H,Guilak F. Chondrogenic potential of adipose tissue-derived stromal cells in vitro and in vivoBiochemical and Biophysical Research CommunicationsYear: 200229027637692-s2.0-003629349811785965
102. Safford KM,Hicok KC,Safford SD,et al. Neurogenic differentiation of murine and human adipose-derived stromal cellsBiochemical and Biophysical Research CommunicationsYear: 200229423713792-s2.0-003629320512051722
103. Cousin B,André M,Arnaud E,Pénicaud L,Casteilla L. Reconstitution of lethally irradiated mice by cells isolated from adipose tissueBiochemical and Biophysical Research CommunicationsYear: 20033014101610222-s2.0-003745908312589814
104. Hosoda T,D’Amario D,Cabral-Da-Silva MC,et al. Clonality of mouse and human cardiomyogenesis in vivoProceedings of the National Academy of Sciences of the United States of AmericaYear: 20091064017169171742-s2.0-7035013260519805158
105. Soonpaa MH,Field LJ. Assessment of cardiomyocyte DNA synthesis in normal and injured adult mouse heartsAmerican Journal of Physiology: Heart and Circulatory PhysiologyYear: 19972721, part 2H220H2262-s2.0-0031013253
106. Walsh S,Pontén A,Fleischmann BK,Jovinge S. Cardiomyocyte cell cycle control and growth estimation in vivo-An analysis based on cardiomyocyte nucleiCardiovascular ResearchYear: 20108633653732-s2.0-7795237102320071355
107. Senyo SE,Steinhauser ML,Pizzimenti CL,et al. Mammalian heart renewal by pre-existing cardiomyocytesNatureYear: 2013493743243343623222518
108. Avery K,Avery S,Shepherd J,Heath PR,Moore H. Sphingosine-1-phosphate mediates transcriptional regulation of key targets associated with survival, proliferation, and pluripotency in human embryonic stem cellsStem Cells and DevelopmentYear: 2008176119512052-s2.0-5744909584818393631
109. Rodgers A,Mormeneo D,Long JS,Delgado A,Pyne NJ,Pyne S. Sphingosine 1-phosphate regulation of extracellular signal-regulated kinase-1/2 in embryonic stem cellsStem Cells and DevelopmentYear: 2009189131913292-s2.0-7035078771019228106
110. Price MM,Kapitonov D,Allegood J,Milstien S,Oskeritzian CA,Spiegel S. Sphingosine-1-phosphate induces development of functionally mature chymase-expressing human mast cells from hematopoietic progenitorsThe FASEB JournalYear: 20092310350635152-s2.0-70349668308
111. Zhao Z,Chen Z,Zhao X,et al. Sphingosine-1-phosphate promotes the differentiation of human umbilical cord mesenchymal stem cells into cardiomyocytes under the designated culturing conditionsJournal of Biomedical ScienceYear: 2011181, article 372-s2.0-79957949939

Article Categories:
  • Review Article

Previous Document:  Use of synthetic single-stranded oligonucleotides as artificial test soiling for validation of surgi...
Next Document:  Immediate care of open extremity fractures: where can we improve?